Tharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and Warrants

Tharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and Warrants

RED BANK, NJ / ACCESS Newswire / July 23, 2025 / Tharimmune, Inc. (the "Company" and "Tharimmune") (Nasdaq Capital Market:THAR), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced the pricing of a registered direct…

Clinical-Stage Biotech Tharimmune Raises $1.74M Through Strategic Stock Offering for Immunology Research

Biotech firm secures fresh capital through stock and warrant offering at $1.786 per unit. Learn how proceeds will advance immunology pipeline development. Get details.